STOCK TITAN

Sight Sciences (SGHT) Financials

SGHT NASDAQ
FY2025 annual
Revenue $77.4M -3.1% YoY
Net Income -$38.4M n/m YoY
EPS (Diluted) -$0.74 n/m YoY
Free Cash Flow -$29.9M n/m YoY
Market Cap $565.8M as of Nov 20, 2026
Price / Sales 6.4x on $88.4M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 11.5x on $49.1M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SGHT SEC filings page.

Sight Sciences, Inc. (SGHT) reported $77.4M in revenue for fiscal year 2025, down 3.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SGHT FY2025

Expense reductions are narrowing losses, but negative cash generation and rising leverage remain central to how this business operates.

Earnings quality is relatively consistent in FY2025: an operating loss of $37.1M was close to a net loss of $38.4M, leaving little difference between operating performance and bottom-line results. From FY2023 to FY2025, revenue fell 4.6% while SG&A fell 18.1%, showing that recent loss improvement came mainly from reducing overhead faster than sales contracted.

Gross margin reached 86.2% even as revenue contracted 3.1%, so the main constraint sits below gross profit rather than in the direct cost of generating sales. SG&A at 115.2% of revenue and R&D at 18.9% still leave operating expenses larger than gross profit, explaining why profitability remains negative.

Cash conversion remains weak: operating cash flow was -$29.7M while free cash flow was -$29.9M, indicating that capital spending is not the primary cash drain. The balance sheet is becoming more debt-dependent, with liabilities at 44.5% of assets and debt-to-equity at 0.6x in FY2025.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 59 / 100
Financial Health Score 59/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Sight Sciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
64

Sight Sciences, Inc. held $92.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $29.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Sight Sciences, Inc. scores 64/100 among other emerging companies.

Dilution
70

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Sight Sciences, Inc. scores 70/100 on it among other emerging companies.

R&D Intensity
42

Sight Sciences, Inc. spent $14.6M on research and development in fiscal year 2025, which was 12.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Sight Sciences, Inc. scores 42/100 among other emerging companies.

Revenue Progress
40

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Sight Sciences, Inc. scores 40/100 on it among other emerging companies.

Burn Trend
68

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Sight Sciences, Inc. scores 68/100 on it among other emerging companies.

Balance Sheet
72

Sight Sciences, Inc.'s cash, cash equivalents and investments came to $92.0M at the end of fiscal year 2025, against $51.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Sight Sciences, Inc. scores 72/100 among other emerging companies.

Altman Z-Score Grey Zone
2.61

Sight Sciences, Inc. scores 2.61, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $565.8M against total liabilities of $51.4M. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
5/9

Sight Sciences, Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing
N/A

Sight Sciences, Inc. reported a net loss of $38.4M while operations used $29.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Sight Sciences, Inc. reported an operating loss of $37.1M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$24.9M
YoY+25.2%
QoQ+6.6%
5Y CAGR+13.7%

Sight Sciences, Inc. generated $24.9M in revenue in Q3 2026. This represents an increase of 25.2% from the same quarter a year earlier. Against the prior quarter it is up 6.6%.

EBITDA
-$6.0M
YoYn/m
QoQn/m
5Y CAGRn/m

Sight Sciences, Inc.'s EBITDA was -$6.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$6.8M
YoYn/m
QoQn/m
5Y CAGRn/m

Sight Sciences, Inc. reported a net loss of $6.8M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.12
YoYn/m
QoQn/m
5Y CAGRn/m

Sight Sciences, Inc. earned -$0.12 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$2.5M
YoYn/m
QoQn/m

Sight Sciences, Inc. recorded an outflow of $2.5M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$77.4M
YoY-16.2%
QoQ-2.9%
5Y CAGR-22.2%

Sight Sciences, Inc. held $77.4M in cash against $35.0M in long-term debt as of Q3 2026.

Shares Outstanding
56M
YoY+5.1%
QoQ+0.9%
5Y CAGR+3.3%

Sight Sciences, Inc. had 56M shares outstanding in Q3 2026. This represents an increase of 5.1% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
85.9%
YoY-0.4pp
QoQ-5.4pp
5Y change+1.7pp

Sight Sciences, Inc.'s gross margin was 85.9% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.4 percentage points.

Operating Margin
-24.6%
YoY+15.1pp
QoQ-8.0pp

Sight Sciences, Inc.'s operating margin was -24.6% in Q3 2026, reflecting core business profitability. This is up 15.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.0 percentage points.

Net Margin
-27.3%
YoY+13.7pp
QoQ-8.3pp

Sight Sciences, Inc.'s net profit margin was -27.3% in Q3 2026, showing the share of revenue converted to profit. This is up 13.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.3 percentage points.

Return on Equity
-13.9%
YoY-1.2pp
QoQ-5.5pp
5Y change-6.9pp

Sight Sciences, Inc.'s quarterly ROE was -13.9% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.5 percentage points.

Capital Allocation

R&D Spending
$2.7M
YoY-19.3%
QoQ+7.7%
5Y CAGR-8.8%

Sight Sciences, Inc. invested $2.7M in research and development in Q3 2026. This represents a decrease of 19.3% from the same quarter a year earlier. Against the prior quarter it is up 7.7%.

Capital Expenditures
$68K
YoY-60.0%
QoQ+257.9%

Sight Sciences, Inc. invested $68K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 60.0% from the same quarter a year earlier. Against the prior quarter it is up 257.9%.

Share Buybacks

Not reported for Q3 2026.

SGHT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SGHT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$24.9M+25.2%$23.4M+19.5%$19.7M+12.5%$20.4M+6.9%$19.9M-1.2%$19.6M-8.5%$17.5M-9.1%$19.1M+1.7%
Cost of Revenue$3.5M+29.3%$2.0M-32.3%$2.7M+12.7%$2.6M+3.3%$2.7M-16.6%$3.0M-1.6%$2.4M-13.6%$2.5M-9.4%
Gross Profit$21.4M+24.6%$21.4M+28.9%$17.0M+12.5%$17.8M+7.4%$17.2M+1.7%$16.6M-9.6%$15.1M-8.4%$16.6M+3.7%
R&D Expenses$2.7M-19.3%$2.5M-42.7%$2.5M-42.5%$2.4M-43.2%$3.4M-29.4%$4.4M+1.6%$4.4M-4.4%$4.3M+25.3%
SG&A Expenses$24.8M+14.2%$22.8M-4.7%$26.8M+9.5%$19.0M-21.4%$21.8M-7.0%$23.9M-10.5%$24.5M-7.7%$24.2M+2.3%
Operating Income-$6.1Mn/m-$3.9Mn/m-$12.4Mn/m-$3.7Mn/m-$7.9Mn/m-$11.7Mn/m-$13.9Mn/m-$11.9Mn/m
EBITDA-$6.0Mn/m-$3.8Mn/m-$12.3Mn/m-$3.6Mn/m-$7.8Mn/m-$11.5Mn/m-$13.7Mn/m-$11.8Mn/m
Interest Expense$1.3M+0.5%$1.3M+0.5%$1.3M+0.4%$1.3M+10.9%$1.3M+13.5%$1.3M+12.1%$1.3M+4.9%$1.2M-14.0%
Income Tax$11Kn/m$28K-30.0%$11K-73.2%$8K-78.9%-$79K-147.6%$40K+166.7%$41K+141.2%$38K+280.0%
Net Income-$6.8Mn/m-$4.4Mn/m-$13.0Mn/m-$4.2Mn/m-$8.2Mn/m-$11.9Mn/m-$14.2Mn/m-$11.8Mn/m
EPS (Basic)-$0.12n/m-$0.08n/m-$0.24n/m-$0.08n/m-$0.16n/m-$0.23n/m-$0.28n/m-$0.24n/m
EPS (Diluted)-$0.12n/m-$0.08n/m-$0.24n/m-$0.08n/m-$0.16n/m-$0.23n/m-$0.28n/m-$0.24n/m
Diluted Shares (Avg)55M+5.2%55M+5.2%54M+5.2%N/A52M+4.0%52M+3.8%51M+3.6%N/A

SGHT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SGHT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$104.9M-9.7%$104.9M-14.0%$109.7M-15.4%$115.3M-19.3%$116.3M-19.0%$122.0M-18.5%$129.7M-16.6%$142.8M-14.3%
Current Assets$101.5M-10.7%$101.4M-15.1%$106.5M-16.1%$112.7M-19.3%$113.6M-19.1%$119.4M-18.4%$126.9M-16.6%$139.8M-14.2%
Cash & Equivalents$77.4M-16.2%$79.8M-21.4%$85.0M-21.9%$92.0M-23.6%$92.4M-22.1%$101.5M-14.1%$108.8M-14.5%$120.4M-12.9%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$6.5M-18.6%$5.7M-8.4%$7.0M+20.7%$7.8M+22.8%$8.0M+31.1%$6.2M-8.4%$5.8M-15.5%$6.3M-19.4%
Accounts Receivable$13.4M+37.3%$11.4M+18.4%$10.6M+12.4%$9.7M-9.7%$9.7M-24.6%$9.6M-51.7%$9.4M-39.8%$10.8M-24.5%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$55.8M+7.4%$52.0M0.0%$55.8M+7.2%$51.4M-7.2%$52.0M+6.8%$52.0M+8.1%$52.1M+12.3%$55.3M+19.1%
Current Liabilities$20.1M+70.2%$20.5M+71.7%$18.2M+49.8%$11.0M-28.7%$11.8M-14.3%$11.9M-10.2%$12.1M+3.7%$15.5M+26.2%
Non-Current Liabilities$35.7M-11.1%$31.5M-21.3%$37.6M-5.7%$40.3M+1.2%$40.1M+15.2%$40.0M+15.0%$39.9M+15.2%$39.8M+16.6%
Long-Term Debt$35.0M-12.7%$30.6M-23.0%$36.7M-7.2%$40.3M+2.4%$40.1M+17.3%$39.8M+17.9%$39.6M+17.5%$39.4M+24.1%
Total Equity$49.1M-23.6%$52.9M-24.5%$53.9M-30.6%$63.9M-26.9%$64.3M-32.3%$70.0M-31.1%$77.6M-28.9%$87.5M-27.2%
Retained Earnings-$409.0Mn/m-$402.1Mn/m-$397.7Mn/m-$384.7Mn/m-$380.6Mn/m-$372.4Mn/m-$360.5Mn/m-$346.3Mn/m

Not reported in any period shown, so not listed: Goodwill.

SGHT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SGHT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$2.4Mn/m-$5.7Mn/m-$7.0Mn/m-$1.8Mn/m-$8.7M-2508.6%-$7.5Mn/m-$11.6Mn/m-$3.5Mn/m
Depreciation & Amortization$110K+4.8%$94K-24.8%$103K-30.9%$108K-38.6%$105K-33.5%$125K-32.8%$149K-22.4%$176K+10.7%
Stock-Based Compensation$2.9M+21.2%$3.0M-22.9%$2.9M-32.8%N/A$2.4M-43.8%$3.8M-11.0%$4.2M-5.8%N/A
Capital Expenditures$68K-60.0%$19K-91.0%$60Kn/mN/A$170K+233.3%$210K+162.5%$0-100.0%$137K-48.1%
Free Cash Flow-$2.5Mn/m-$5.7Mn/m-$7.1Mn/mN/A-$8.9M-2958.2%-$7.8Mn/m-$11.6Mn/m-$3.6Mn/m
Investing Cash Flow-$68Kn/m-$19Kn/m-$60Kn/m$156Kn/m-$170Kn/m-$210Kn/m$0n/m-$137Kn/m
Financing Cash Flow$119K+376.0%$474K-2.3%$88K+450.0%$1.3M-76.5%$25K-67.1%$485K+10.0%$16Kn/m$5.4M+1333.2%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SGHT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SGHT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin85.9%-0.4pp91.4%+6.6pp86.2%0.0pp87.3%+0.4pp86.4%+2.5pp84.8%-1.1pp86.2%+0.7pp86.8%+1.6pp
Operating Margin-24.6%+15.1pp-16.6%+43.0pp-63.0%+16.1pp-18.0%+44.5pp-39.7%+16.0pp-59.6%-0.4pp-79.2%-2.7pp-62.5%-3.3pp
Net Margin-27.3%+13.7pp-19.0%+42.0pp-65.9%+14.9pp-20.4%+41.7pp-41.0%+13.9pp-61.0%-3.4pp-80.8%+3.6pp-62.1%-5.1pp
Return on Equity-13.9%-1.2pp-8.4%+8.7pp-24.1%-5.8pp-6.5%+7.0pp-12.7%-1.1pp-17.1%-4.9pp-18.2%-3.3pp-13.5%-4.6pp
Return on Assets-6.5%+0.5pp-4.2%+5.5pp-11.8%-0.9pp-3.6%+4.7pp-7.0%+0.7pp-9.8%-1.6pp-10.9%-0.5pp-8.3%-1.9pp
Current Ratio5.04-4.6x4.95-5.1x5.86-4.6x10.22+1.2x9.60-0.6x10.01-1.0x10.47-2.5x9.04-4.3x
Debt-to-Equity0.71+0.1x0.580.0x0.68+0.2x0.63+0.2x0.62+0.3x0.57+0.2x0.51+0.2x0.45+0.2x
Liabilities-to-Equity1.14+0.3x0.98+0.2x1.04+0.4x0.80+0.2x0.81+0.3x0.74+0.3x0.67+0.2x0.63+0.2x
Asset Turnover0.24+0.1x0.22+0.1x0.180.0x0.180.0x0.170.0x0.160.0x0.140.0x0.130.0x
FCF Margin-9.9%+34.7pp-24.3%+15.3pp-36.0%+30.3ppN/A-44.6%-46.2pp-39.6%+5.0pp-66.3%-14.9pp-18.9%+17.1pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Sight Sciences, Inc. SGHT FY2025 $77.4M -$38.4M -49.7% $565.8M 59/100
Tactile Systems Technology, Inc. TCMD FY2025 $329.5M $19.1M 5.8% $573.5M 69/100
Delcath Systems Inc DCTH FY2025 $85.2M $2.7M 3.2% $653.7M 52/100
QuidelOrtho Corporation QDEL FY2025 $2.7B -$1.1B -41.4% $570.9M 21/100
Avita Medical, Inc. RCEL FY2025 $71.6M -$48.6M -67.8% $480.7M 48/100
Bioventus Inc. BVS FY2025 $568.1M $22.7M 4.0% $676.5M 43/100

Frequently Asked Questions

Sight Sciences, Inc. (SGHT) reported $77.4M in total revenue for fiscal year 2025. This represents a -3.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Sight Sciences, Inc. (SGHT) revenue declined by 3.1% year-over-year, from $79.9M to $77.4M in fiscal year 2025.

No, Sight Sciences, Inc. (SGHT) reported a net loss of $38.4M in fiscal year 2025, with a net profit margin of -49.7%.

Sight Sciences, Inc. (SGHT) reported diluted earnings per share of -$0.74 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sight Sciences, Inc. (SGHT) had EBITDA of -$36.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Sight Sciences, Inc. (SGHT) had $92.0M in cash and equivalents against $40.3M in long-term debt.

Sight Sciences, Inc. (SGHT) had a gross margin of 86.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Sight Sciences, Inc. (SGHT) had an operating margin of -47.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Sight Sciences, Inc. (SGHT) had a net profit margin of -49.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Sight Sciences, Inc. (SGHT) has a return on equity of -60.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Sight Sciences, Inc. (SGHT) recorded an outflow of $29.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Sight Sciences, Inc. (SGHT) recorded an outflow of $29.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Sight Sciences, Inc. (SGHT) had $115.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Sight Sciences, Inc. (SGHT) invested $224K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Sight Sciences, Inc. (SGHT) invested $14.6M in research and development during fiscal year 2025.

Sight Sciences, Inc. (SGHT) had 54M shares outstanding as of fiscal year 2025.

Sight Sciences, Inc. (SGHT) had a current ratio of 10.22 as of fiscal year 2025, which is generally considered healthy.

Sight Sciences, Inc. (SGHT) had a debt-to-equity ratio of 0.63 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Sight Sciences, Inc. (SGHT) had a liabilities-to-equity ratio of 0.80 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Sight Sciences, Inc. (SGHT) had a return on assets of -33.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Sight Sciences, Inc. (SGHT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $565.8M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Sight Sciences, Inc. (SGHT) trades at 6.4x sales, its market capitalization divided by $88.4M revenue, trailing 12 months to September 30, 2026. The market capitalization is $565.8M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Sight Sciences, Inc. (SGHT) held $92.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.7M over that year. Dividing the one by the other, the reported balance equals about 37 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Sight Sciences, Inc. (SGHT) has an Altman Z-Score of 2.61, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Sight Sciences, Inc. (SGHT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Sight Sciences, Inc. (SGHT) reported a net loss of $38.4M while operations used $29.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Sight Sciences, Inc. (SGHT) reported an operating loss of $37.1M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Sight Sciences, Inc. (SGHT) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top